Rapid test shows 'solid performance' for diagnosing infection around joint implants

November 09, 2020

November 9, 2020 - The recently FDA-authorized alpha-defensin lateral flow test is a highly accurate, ten-minute test for diagnosis of periprosthetic joint infection (PJI) - a serious and costly complication of total joint replacement, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.

The study shows "solid diagnostic performance" of the alpha-defensin lateral flow test, according to the report by Carl Deirmengian, MD, of The Rothman Orthopedic Institute, Wynnewood, Pa., and colleagues. The data led to US Food and Drug Administration authorization of the new test: the first rapid test for specifically designed and validated to aid in the diagnosis of PJI. The alpha-defensin test also represents the first diagnostic test specifically designed for use in orthopedics.

Lateral flow test enables faster, simpler diagnosis of PJI

Periprosthetic joint infection is a devastating complication of failed total hip or knee replacement, and one that can be challenging for orthopedic surgeons to diagnose. Accounting for 25 percent of total knee replacement failures and 16 percent of total hip replacement failures, PJI has a major impact on patients' lives and health-care costs.

Alpha defensins are peptides produced by the immune system specifically in response to an infection. The new test measures alpha-defensin levels in samples of synovial fluid from the joint. The new alpha-defensin lateral flow test is a simple test kit that provides results in 10 to 20 minutes. An alpha-defensin enzyme-linked immunosorbent assay (ELISA) is also available. With the ELISA, the sample must be sent to a laboratory, providing results in 24 to 48 hours.

Dr. Deirmengian and colleagues designed a formal study to evaluate the performance of the alpha-defensin lateral flow test in diagnosing PJI. The study included synovial fluid samples from 305 patients with knee (203 patients) or hip (102 patients) arthroplasties. Of these, 57 patients had PJI, based on expert review.

The alpha-defensin lateral flow test was highly accurate in distinguishing between patients with and without PJI. The sensitivity and specificity of the alpha-defensin lateral flow test was 94.3 percent and 94.5 percent, respectively, when excluding rare poor-quality synovial fluid samples that were composed of substantial blood (greater than 1M RBCs/μL). Including even the poor-quality samples, the test had a sensitivity of 89.5 percent and specificity of 94.8 percent.

Another important finding was that the diagnostic performance of the rapid lateral flow assay matched the accuracy of the laboratory-based test for alpha-defensin. Both tests demonstrated a diagnostic performance that closely matched the standard approach to PJI diagnosis, based on a combination of clinical findings and laboratory tests (Musculoskeletal Infection Society criteria).

"Our study enhances the literature by extending the evaluation of alpha defensin to a formal diagnostic trial, thus confirming the solid diagnostic performance demonstrated by previous studies using other methods." Dr. Deirmengian and coauthors write. They emphasize the need for further studies to compare different approaches to diagnosis in patients with suspected PJI.
-end-
The study was sponsored by Zimmer Biomet, manufacturer of the Synovasure® alpha-defensin lateral flow and ELISA tests.

Click here to read "Validation of the Alpha Defensin Lateral Flow Test for Periprosthetic Joint Infection."

DOI: 10.2106/JBJS.20.00749

###


About The Journal of Bone & Joint Surgery

The Journal of Bone & Joint Surgery(JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.

About Wolters Kluwer

Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.

Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students with advanced clinical decision support, learning and research and clinical intelligence. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.

For more information, visit http://www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.

Wolters Kluwer Health

Related Knee Replacement Articles from Brightsurf:

Study compares racial disparities in unilateral versus bilateral knee replacement
Analyzing data from the NIS - Healthcare Cost and Utilization Project database, researchers at Hospital for Special Surgery (HSS) found that African Americans were much less likely to undergo bilateral knee replacement compared to white patients.

Steroid injections do not hasten the need for knee replacement
New research shows that corticosteroid injections for knee OA treatment do not hasten a patient's progression to a total knee replacement when compared with hyaluronic acid injections.

Warfarin use significantly increases risk of knee and hip replacement in people with OA
New research shows that use of warfarin is associated with a significantly greater risk of knee and hip replacements in patients with OA.

Younger knee replacement patients more likely to require reoperation
Knee replacement surgery, also known as total knee arthroplasty (TKA), is increasing among patients 65 and younger.

Osteoarthritis: Conservative therapy delays need for knee and hip joint replacement surgery
With implementation of conservative treatment methods like physiotherapy and individually tailored, adjusted exercises, quality of osteoarthritis care can improve and patients can delay the need for an artificial hip or knee joint.

Changes in opioid use after hip, knee replacement
Researchers looked at changes in opioid prescribing rates and level of pain control in patients who had hip or knee replacement in the U.S. from 2014 to 2017.

Knee replacement timing is all wrong for most patients
The timing of knee replacement surgery is critical to optimize its benefit.

Study: 'Pre-habilitation' by peer coaches before knee replacement may improve outcomes
HSS researchers launched a study to see if a 'pre-habilitation'' program - counseling by a peer coach who has already had knee replacement - could empower and inform patients scheduled for the surgery and lead to better outcomes.

Study finds racial variation in post-op care after knee replacement surgery
A large study analyzing 107,000 knee replacement surgeries found that African Americans were significantly more likely than white patients to be discharged to an inpatient rehabilitation or skilled nursing facility rather than home care after the procedure.

Race and poverty not risk factors for total knee replacement revision or failure
In a new study published in Arthritis Care & Research, HSS investigators found race and poverty are not risk factors for total knee replacement revision or failure at a high-volume orthopedic hospital.

Read More: Knee Replacement News and Knee Replacement Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.